Back to Search
Start Over
AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
- Source :
- Blood; November 2013, Vol. 122 Issue: 21 p240-240, 1p
- Publication Year :
- 2013
-
Abstract
- Yen: Agios Pharmaceuticals: Employment, Equity Ownership. Wang:Agios Pharmaceuticals: Employment, Equity Ownership. Travins:Agios Pharmaceuticals: Employment, Equity Ownership. Chen:agios Pharmaceuticals: Employment, Equity Ownership. Yang:Agios Pharmaceuticals: Employment, Equity Ownership. Straley:Agios Pharmaceuticals: Employment, Equity Ownership. Choe:agios Pharmaceuticals: Employment, Equity Ownership. Dorsch:agios Pharmaceuticals: Employment, Equity Ownership. Schenkein:agios Pharmaceuticals: Employment, Equity Ownership. Agresta:agios Pharmaceuticals: Employment, Equity Ownership. Biller:agios Pharmaceuticals: Employment, Equity Ownership. Su:agios Pharmaceuticals: Employment, Equity Ownership.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 122
- Issue :
- 21
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53002284
- Full Text :
- https://doi.org/10.1182/blood.V122.21.240.240